A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
Latest Information Update: 02 Jul 2024
At a glance
- Drugs Tifcemalimab (Primary) ; Toripalimab (Primary)
- Indications Lymphoma; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Shanghai Junshi Biosciences
- 04 Jun 2024 Results (n=85; by 16 Dec 2023) reporting dose escalation and cohort expansion data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2022 According to Junshi Biosciences media release, results presented at at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting